CN108289932A - 胞外dna作为神经变性的治疗靶点 - Google Patents

胞外dna作为神经变性的治疗靶点 Download PDF

Info

Publication number
CN108289932A
CN108289932A CN201680042916.0A CN201680042916A CN108289932A CN 108289932 A CN108289932 A CN 108289932A CN 201680042916 A CN201680042916 A CN 201680042916A CN 108289932 A CN108289932 A CN 108289932A
Authority
CN
China
Prior art keywords
dnase
patient
administered
pharmaceutical composition
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680042916.0A
Other languages
English (en)
Chinese (zh)
Inventor
D·D·格恩金
G·V·苔兹
V·V·苔兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN108289932A publication Critical patent/CN108289932A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/02—Thioester hydrolases (3.1.2)
    • C12Y301/02021—Dodecanoyl-[acyl-carrier-protein] hydrolase (3.1.2.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201680042916.0A 2015-05-22 2016-05-11 胞外dna作为神经变性的治疗靶点 Pending CN108289932A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562165255P 2015-05-22 2015-05-22
US62/165,255 2015-05-22
PCT/RU2016/000284 WO2016190780A1 (en) 2015-05-22 2016-05-11 Extracellular dna as a therapeutic target in neurodegeneration

Publications (1)

Publication Number Publication Date
CN108289932A true CN108289932A (zh) 2018-07-17

Family

ID=57393467

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680042916.0A Pending CN108289932A (zh) 2015-05-22 2016-05-11 胞外dna作为神经变性的治疗靶点

Country Status (7)

Country Link
US (1) US11701410B2 (https=)
EP (1) EP3297657B1 (https=)
JP (1) JP6745873B2 (https=)
CN (1) CN108289932A (https=)
ES (1) ES2799515T3 (https=)
RU (1) RU2726131C2 (https=)
WO (1) WO2016190780A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110129245A (zh) * 2019-07-08 2019-08-16 南京工业大学 一株敲除胞外核酸酶ExeP的谷氨酸棒杆菌及其构建方法与应用

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016190780A1 (en) 2015-05-22 2016-12-01 Dmitry Dmitrievich Genkin Extracellular dna as a therapeutic target in neurodegeneration
US20190083636A1 (en) * 2017-04-25 2019-03-21 Lipoxen Technologies Limited Methods of treating diseases related to net formation with parenteral administration of polysialylated dnase i
US12274720B2 (en) 2017-05-24 2025-04-15 Viktor Veniaminovich Tets Methods for treating and preventing diseases
ES2913665T3 (es) 2017-09-18 2022-06-03 Santersus Ag Método y dispositivo para la purificación de sangre a partir de ADN celular libre en circulación
KR20200122320A (ko) 2018-01-16 2020-10-27 씨엘에스 테라퓨틱스 리미티드 데옥시리보뉴클레아제 (dnase) 활성을 갖는 효소의 간 발현에 의한 질환의 치료
CA3098444A1 (en) 2018-04-30 2019-11-07 Viktor Veniaminovich Tets Tetz-proteins and prion-like proteins and associated methods
US12480150B2 (en) 2018-06-29 2025-11-25 Viktor Veniaminovich Tets and Georgy Viktorovich TETS Compositions for modulating gut microbiota
WO2020006357A1 (en) 2018-06-29 2020-01-02 Tets Viktor Veniaminovich Methods for diagnosis and treatment of type 1 diabetes
WO2020010214A1 (en) 2018-07-03 2020-01-09 Tets Viktor Veniaminovich Method for assessing and inhibiting aging and means of determining biological age
CA3147034A1 (en) * 2019-07-12 2021-01-21 Cls Therapeutics Limited Treatment of diseases associated with protein misfolding by nervous system expression of an enzyme which has a deoxyribonuclease (dnase) activity
EP4119149A1 (en) * 2021-07-15 2023-01-18 Foundation For Research And Technology Hellas Extracellular vesicles comprising a therapeutic cargo
WO2023126672A1 (en) 2021-12-27 2023-07-06 Santersus Ag Method and device for removal of circulating cell free dna

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003068254A1 (en) * 2002-02-18 2003-08-21 University Of Southampton Glycosaminoglycan-dnase combination therapy
US20050043312A1 (en) * 2003-07-25 2005-02-24 Shea Thomas B. Formulations for reducing neuronal degeneration
CN101171034A (zh) * 2005-03-03 2008-04-30 免疫医疗公司 人源化l243抗体
EP2095825A1 (en) * 2006-11-28 2009-09-02 GENKIN, Dmitry Dmitrievich Method for treating human diseases associated with an increased deoxyribonucleic acid content in extracellular spaces of tissues and a medicinal preparation for carrying out said method
EP2497486A1 (en) * 2003-07-14 2012-09-12 CLS Therapeutics Limited Method for treating diseases caused by fungi associated with changes of qualitative and/quantitative composition of blood extracellular DNA
CN103221072A (zh) * 2010-12-02 2013-07-24 免疫医疗公司 用于递送治疗剂和/或诊断剂的体内无铜催化的点击化学

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3224942A (en) 1962-01-15 1965-12-21 Rorer Inc William H Anti-inflammatory, anti-edema and anti-thrombi drug
US3324002A (en) 1962-09-17 1967-06-06 Armour Pharma Anti-inflammatory preparations containing proteolytic enzymes and adrenal glucocorticoids
JPS5826822A (ja) 1981-08-10 1983-02-17 Kaken Pharmaceut Co Ltd 慢性腎炎治療剤
JPS61293927A (ja) 1986-06-18 1986-12-24 Kaken Pharmaceut Co Ltd 肝臓疾患予防治療剤
US4985243A (en) 1988-01-20 1991-01-15 Ml Technology Ventures, L.P. Composition and method for protecting against diseases caused by microorganisms
ATE176924T1 (de) 1988-12-23 1999-03-15 Genentech Inc Verfahren zur herstellung von menschlicher dnase
US5464817A (en) 1990-04-11 1995-11-07 Brigham And Women's Hospital Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
DE4024530A1 (de) 1990-08-02 1992-02-06 Klinger & Co Dr Verfahren zur bekaempfung von viren
FR2666096B1 (fr) 1990-08-21 1993-12-31 Sfri Sa Nouveau procede de dosage d'acide desoxyribonucleique present en position extracellulaire dans un milieu.
DE69207603T2 (de) 1991-08-16 1996-09-12 Vical Inc Zusammensetzung und verfahren zur behandlung von zystischer fibrose
US5484589A (en) 1992-04-20 1996-01-16 Rufeld, Inc. Anti-viral methods using RNAse and DNAse
NZ299257A (en) 1992-06-08 2000-08-25 Genentech Inc Treating purulent material (eg pulmonary disease) accumulation in patients using deamidated DNase
WO1995000170A1 (en) 1993-06-24 1995-01-05 Rufeld, Inc. Inhibition of human immunodeficiency virus reproduction by deoxyribonuclease i
CH686982A5 (fr) 1993-12-16 1996-08-15 Maurice Stroun Méthode pour le diagnostic de cancers.
RU2099080C1 (ru) 1994-02-11 1997-12-20 Дмитрий Иванович Финько Способ предотвращения развития рака
CA2184582C (en) 1994-03-04 2001-12-25 Hak-Kim Chan Pharmaceutically acceptable dnase formulation
US5830744A (en) 1995-06-06 1998-11-03 Human Genome Sciences, Inc. Gene encoding human Dnase
US5889153A (en) 1994-05-20 1999-03-30 Hisamitsu Pharmaceutical Co., Inc. Protein or polypeptide, method for producing the same and intermediate compound therefor
JP4118334B2 (ja) 1996-02-05 2008-07-16 ジェネンテック・インコーポレーテッド ヒトｄｎアーゼ
AU2324997A (en) 1996-03-15 1997-10-01 Penn State Research Foundation, The Detection of extracellular tumor-associated nucleic acid in blood plasma or ser um using nucleic acid amplification assays
US6391607B1 (en) 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants
US5855920A (en) 1996-12-13 1999-01-05 Chein; Edmund Y. M. Total hormone replacement therapy
US6242426B1 (en) 1997-07-25 2001-06-05 Avigen, Inc. Induction of immune response to antigens expressed by recombinant adeno-associated virus
US6455250B1 (en) 1997-12-11 2002-09-24 The Regents Of The University Of California Endonuclease compositions and methods of use
WO2000003709A1 (en) 1998-07-16 2000-01-27 Research Development Foundation Novel dna-cleaving antitumor agents
US6465177B1 (en) 1998-10-26 2002-10-15 John Wayne Cancer Institute Detection of loss of heterozygosity in tumor and serum of melanoma patients
CA2352486A1 (en) 1998-11-25 2000-06-02 Genetica, Inc. Methods and reagents for increasing proliferative capacity and preventing replicative senescence
JP2000229881A (ja) 1999-02-10 2000-08-22 Morinaga Milk Ind Co Ltd 癌疾患の予後改善剤
JP4522632B2 (ja) 1999-08-17 2010-08-11 靖一 田沼 新規デオキシリボヌクレアーゼ、それをコードする遺伝子およびそれらの用途
US6428785B1 (en) 1999-10-28 2002-08-06 Immunolytics Inc. Method and composition for treating prostate cancer
UA78486C2 (uk) 1999-12-10 2007-04-10 Хемджен Корпорейшн Композиція для перорального введення птахам та тваринам для лікування або зниження ризику інфекції травного тракту (варіанти), її застосування (варіанти) та спосіб лікування або зниження ризику інфекцій травного тракту (варіанти)
AU4430701A (en) 2000-04-03 2001-10-15 Antisoma Research Limited Compounds for targeting
US6462017B1 (en) 2000-05-01 2002-10-08 Sciclone Pharmaceuticals, Inc. Method of reducing side effects of chemotherapy in cancer patients
RU2202109C1 (ru) 2001-08-03 2003-04-10 Научно-исследовательский институт неврологии РАН Способ выявления степени нарушения реологических свойств крови
RU2207876C1 (ru) 2001-11-08 2003-07-10 Ткаченко Виталий Васильевич Способ комплексно-индивидуализированного воздействия на организм при медленной вирусной инфекции и способ подготовки лабораторного животного для испытания способа такого воздействия
US7402724B2 (en) 2002-01-04 2008-07-22 Mayo Foundation For Medical Education And Research Longevity and PAPP-A
DE10221194B4 (de) 2002-05-13 2005-02-10 Fryda, Waltraud, Dr.med. Hyaluronidasehaltiges Hautpflegemittel
US20040001817A1 (en) 2002-05-14 2004-01-01 Giampapa Vincent C. Anti-aging nutritional supplement
EP1431762B1 (en) 2002-12-18 2007-04-25 Coy, Johannes F., Dr. Compounds and methods for detection of carcinomas and their precursor lesions
RU2239442C1 (ru) 2003-05-05 2004-11-10 Красноярская государственная медицинская академия Способ профилактики внутриутробных инфекций у детей
US8431123B2 (en) 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
RU2269356C2 (ru) 2003-07-14 2006-02-10 Дмитрий Дмитриевич Генкин Способ лечения онкологических заболеваний
EP1666055A4 (en) 2003-07-14 2010-02-10 Viktor Veniaminovich Tets METHOD OF TREATMENT OF ONCOLOGICAL, INFECTIOUS, AND SOMATIC DISEASES, METHODS OF MONITORING THE EFFICACY OF TREATMENT, AGENTS AND PHARMACEUTICAL COMPOSITIONS THEREOF
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
WO2005004904A1 (en) 2003-07-14 2005-01-20 Dmitry Dmitrievich Genkin Method for treating diseases associated with modifications of qualitative and/ quantitative composition of blood extracellular dna (variants)
US8710012B2 (en) 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
RU2269359C2 (ru) 2004-03-12 2006-02-10 Дмитрий Дмитриевич Генкин Способ профилактики развития онкологических заболеваний или инфекций, вызываемых бактериями, грибами и простейшими, или атеросклероза, или сахарного диабета, или заболеваний, связанных с реакцией гиперчувствительности замедленного типа, или заболеваний, развивающихся вследствие мутации генов соматических клеток (варианты)
RU2239404C1 (ru) 2003-09-17 2004-11-10 Бессонов Дмитрий Михайлович Способ профилактики старения организма человека
RU2267329C2 (ru) 2004-03-12 2006-01-10 Дмитрий Дмитриевич Генкин Способ лечения заболеваний, сопровождающихся изменениями качественного и/или количественного состава внеклеточной днк крови (варианты)
RU2269357C2 (ru) 2004-03-12 2006-02-10 Дмитрий Дмитриевич Генкин Способ замедления наступления болезненных состояний, связанных с увеличением возраста человека
CA2604243C (en) 2004-04-14 2015-11-24 Avirid, Inc. Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases
JP3989936B2 (ja) 2005-04-07 2007-10-10 進 須永 抗腫瘍剤及び新規ｄｎアーゼ
US8916151B2 (en) 2005-04-25 2014-12-23 Cls Therapeutics Limited Method for treating a reduction of fertility
BRPI0616012A2 (pt) 2005-07-18 2011-05-31 Protalix Ltd administração via mucosa ou intestino de macromoléculas biologicamente ativas
RU2308968C2 (ru) 2005-07-19 2007-10-27 Дмитрий Дмитриевич Генкин Способ лечения заболеваний человека, сопровождающихся повышенным содержанием дезоксирибонуклеиновой кислоты во внеклеточных пространствах тканей, и лекарственный препарат для его реализации
WO2008039989A2 (en) * 2006-09-28 2008-04-03 Transave, Inc. Formulations of dnase and methods of use thereof
PT2086642E (pt) 2006-10-18 2014-09-30 Periness Ltd Dnase para o tratamento de subfertilidade masculina
GB0922006D0 (en) 2009-12-17 2010-02-03 Genome Res Ltd Diagnostic
US20130243794A1 (en) 2010-12-03 2013-09-19 Beth Israel Deaconess Medical Center, Inc. Methods for predicting and treating infection-induced illnesses and predicting the severity of infection-induced illnesses
US9603907B2 (en) 2012-02-01 2017-03-28 Protalix Ltd. Dry powder formulations of dNase I
AU2013221212B2 (en) 2012-02-17 2018-08-09 The Children's Hospital Of Philadelphia AAV vector compositions and methods for gene transfer to cells, organs and tissues
JP6285436B2 (ja) 2012-08-03 2018-02-28 フェリング ベスローテン フェンノートシャップ 雌性不妊症のための治療標的および診断マーカーとしての無細胞ｄｎａ
HUE052676T2 (hu) 2013-10-11 2021-05-28 Massachusetts Eye & Ear Infirmary Eljárások õsi vírusszekvenciák elõrejelzésére és alkalmazásaik
CA2943296C (en) 2014-03-21 2022-10-18 The Sydney Children's Hospitals Network (Randwick And Westmead) (Incorporating The Royal Alexandra Hospital For Children) Stable gene transfer to proliferating cells
WO2016081811A1 (en) 2014-11-21 2016-05-26 The University Of North Carolina At Chapel Hill Aav vectors targeted to the central nervous system
WO2016190780A1 (en) 2015-05-22 2016-12-01 Dmitry Dmitrievich Genkin Extracellular dna as a therapeutic target in neurodegeneration
RU2021102893A (ru) 2015-11-05 2021-03-03 Бамбу Терапьютикс, Инк. Модифицированные гены атаксии фридрейха и векторы для генной терапии
CA3015353A1 (en) 2016-02-25 2017-08-31 Agenovir Corporation Viral and oncoviral nuclease treatment

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003068254A1 (en) * 2002-02-18 2003-08-21 University Of Southampton Glycosaminoglycan-dnase combination therapy
EP2497486A1 (en) * 2003-07-14 2012-09-12 CLS Therapeutics Limited Method for treating diseases caused by fungi associated with changes of qualitative and/quantitative composition of blood extracellular DNA
US20050043312A1 (en) * 2003-07-25 2005-02-24 Shea Thomas B. Formulations for reducing neuronal degeneration
CN101171034A (zh) * 2005-03-03 2008-04-30 免疫医疗公司 人源化l243抗体
EP2095825A1 (en) * 2006-11-28 2009-09-02 GENKIN, Dmitry Dmitrievich Method for treating human diseases associated with an increased deoxyribonucleic acid content in extracellular spaces of tissues and a medicinal preparation for carrying out said method
CN103221072A (zh) * 2010-12-02 2013-07-24 免疫医疗公司 用于递送治疗剂和/或诊断剂的体内无铜催化的点击化学

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GLEBOVA KV等: "Properties of Extracellular DNA from the Cerebrospinal Fluid and Blood Plasma during Parkinson’s Disease", 《BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110129245A (zh) * 2019-07-08 2019-08-16 南京工业大学 一株敲除胞外核酸酶ExeP的谷氨酸棒杆菌及其构建方法与应用

Also Published As

Publication number Publication date
EP3297657B1 (en) 2020-03-25
EP3297657A1 (en) 2018-03-28
RU2726131C2 (ru) 2020-07-09
JP2018520208A (ja) 2018-07-26
JP6745873B2 (ja) 2020-08-26
RU2017145051A (ru) 2019-06-24
RU2017145051A3 (https=) 2019-06-24
WO2016190780A1 (en) 2016-12-01
EP3297657A4 (en) 2018-11-14
US11701410B2 (en) 2023-07-18
US20180360925A1 (en) 2018-12-20
ES2799515T3 (es) 2020-12-18

Similar Documents

Publication Publication Date Title
CN108289932A (zh) 胞外dna作为神经变性的治疗靶点
Sedel et al. Targeting demyelination and virtual hypoxia with high-dose biotin as a treatment for progressive multiple sclerosis
US20260034156A1 (en) Inhibitors of sarm1 in combination with nad+ or a nad+ precursor
US12083114B2 (en) Inhibitors of SARM1 in combination with neuro-protective agents
Ruscher et al. The involvement of the sigma-1 receptor in neurodegeneration and neurorestoration
Zhang et al. Endoplasmic reticulum stress: relevance and therapeutics in central nervous system diseases
Ingwersen et al. Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy
JP4316373B2 (ja) ヒトのアセチルコリンエステラーゼ（ａｃｈｅ）に対するアンチセンスオリゴヌクレオチド及びその使用
US12595481B2 (en) Methods and compositions for neuroprotection
JP2020062022A (ja) ＴＡＴｋ−ＣＤＫＬ５融合タンパク質、組成物、製剤、及びそれらの使用
Guo et al. The renin-angiotensin system regulates neurodegeneration in a mouse model of optic neuritis
EP3074034B1 (en) Treatment of inflammatory disease using caveolin linked to an internalisation peptide
JP2017507655A5 (https=)
US20240100076A1 (en) Methods and compositions for treating neurodegenerative diseases
Oz et al. The role of nicotinic acetylcholine receptors in the pathophysiology and pharmacotherapy of autism spectrum disorder: focus on α7 nicotinic receptors
US20130197069A1 (en) Methods for treating stress induced emotional disorders
Claeys et al. Epilepsy and migraine in a patient with Urbach–Wiethe disease
BR112020013994A2 (pt) Oligonucleotídeos antissenso que direcionam alfa-sinucleína e seus usos
US10314835B2 (en) Methods of managing conditioned fear with neurokinin receptor antagonists
CN100525764C (zh) 吡唑并吡啶在制备治疗认知缺陷的药物中的应用
CA3190597A1 (en) Compositions and methods for the treatment of ocular neuroinflammation
WO2003097024A1 (en) Methods for the prevention and/or the treatment of neurological disorders
IT201900010722A1 (it) Composto e composizione per il trattamento multi-obiettivo di disturbi legati alla proteina tau
WO2013091008A1 (en) Method of treating reduced ceruloplasmin functionality in the central nervous system
Phoebe et al. Qi Li*, Wai Man Chan, John A. Rudd⁺, Chun Mei Wang Phoebe Y. H. Lam

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180717